Navigation Links
Actinium Pharmaceuticals Commences Screening for the Second Cohort of Patients in the Company's Ongoing Phase I/II Trial in Acute Myeloid Leukemia
Date:9/7/2012

NEW YORK, Sept. 7, 2012 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (API), a biopharmaceutical company that develops innovative targeted payload immunotherapeutics, announced that the Company is moving forward with enrollment and treatment of additional patients in its clinical trial for acute myeloid leukemia (AML) in patients over the age of 60. Actinium will proceed with patient screening and enrollment for the second cohort, who, in keeping with trial protocol, will be injected with two times higher activity of the Company's investigational new drug Actimab-A. 

"This is a significant milestone for our company," commented Jack Talley, CEO of Actinium Pharmaceuticals. "Our program is now advancing rapidly, offering new hope for patients who were until now generally considered untreatable, as additional leading cancer treatment centers continue to join our trial." 

The trial is a prospective, open-label study, designed to determine the safety and efficacy of Actimab-A in newly diagnosed AML patients who cannot tolerate current high dose chemotherapeutic regimens. 

Mr. Talley added, "Acute myeloid leukemia in patients over the age of 60 is a serious unmet need and we are eager to make this treatment available to patients."

Actimab-A is being developed using Company's proprietary patented APIT technology and it consists of the monoclonal antibody Lintuzumab used to guide the alpha emitting radioisotope actinium 225 to malignant cells.

About actinium 225

Actinium-225 decays by giving off high-energy alpha particles, which kill cancer cells. When actinium decays, it produces a series of daughter atoms, each of which gives off its own alpha particle, increasing the chances that the cancer cell will be destroyed.  The technology was first demonstrated by Dr. David Scheinberg at Memorial Sloan Kettering Cancer Center. 

About Lintuzumab (HuM195)

Lintuzumab is a monoclonal antibody that targets CD33, found on myeloid leukemia cells. It is the humanized version of M195, the antibody initially developed by Dr. David Scheinberg of Memorial Sloan Kettering Cancer Center.

Acute Myeloid Leukemia is the most difficult to treat form of leukemia.  The majority of patients do not qualify for the commonly used chemotherapy regimen and their median survival following diagnosis is about 2 months without treatment.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc. is a Newark, New Jersey based biopharmaceutical company that develops innovative alpha particle immunotherapeutics based on its proprietary platform for the therapeutic utilization of alpha particle emitting actinium-225 and bismuth-213 radiopharmaceuticals in association with monoclonal antibodies.

For more information:

Visit our web site www.actiniumpharmaceuticals.com or contact:

Media:
Dennis S. Dobson Jr., 203-258-0159
Email: dsdobson@optonline.com
www.dobsonmediagroup.com

Jack Talley, CEO
Actinium Pharmaceuticals Inc.
Tel:  (646) 459-4201
E-mail: actimaba@actiniumpharmaceuticals.com

Investors:
Jeff Ramson
ProActive Capital Group, LLC
Tel:  (646) 863-6341
E-mail: jramson@proactivecrg.com
www.proactivecrg.com  

Forward-Looking Statement for Actinium Pharmaceuticals, Inc.

This news release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance.  No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

E-mail: dcicic@actiniumpharmaceuticals.com


'/>"/>
SOURCE Actinium Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Actinium Pharmaceuticals Inc. Pays Regulatory Milestone to Abbott Biotherapeutics Corp.
2. Actinium Pharmaceuticals Announces The Addition of The Fred Hutchinson Cancer Research Center To Actiniums Multicenter Clinical Trial For Patients With Acute Myeloid Leukemia
3. Actinium Pharmaceuticals and Philogen S.p.A. Announce Collaboration for Alpha Therapy Based Antiangiogenesis Program
4. Actinium Pharmaceuticals Strengthens Management Team
5. Actinium Pharmaceuticals Stockholders Vote to Approve Fundraising and Public Listing
6. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
7. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
8. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
9. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
10. Icahn Issues Statement Regarding Amylin Pharmaceuticals
11. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... , March 29, 2017  Maxor National Pharmacy Services, ... that it has named Leah Bailey as ... divisions of the company. With more than ... previous 8 years focused on health care, Bailey joins ... tenure at Prime, Bailey advised the PBM, Specialty, and ...
(Date:3/29/2017)... March 29, 2017  Designers of primary cell wearable ... size by 50% and extend battery life with the ... integrated circuit (PMIC) from Maxim Integrated Products, Inc. (NASDAQ: ... low input voltage of just 0.7V for new high-energy ... Oxide, as well as the more common Alkaline battery ...
(Date:3/29/2017)... , USA, March 29, 2017 Stryker ... that Cares by People magazine, in partnership with Great ... 50 companies on the list. This list highlights the ... have succeeded in business while also demonstrating respect, compassion ... environment.  To determine the companies on ...
Breaking Medicine Technology:
(Date:3/29/2017)... (PRWEB) , ... March 29, 2017 , ... AvePoint ... seventh North American office location in Richmond, Virginia, located at the Riverfront Plaza, 901 ... attended by Lieutenant Governor of Virginia Ralph S. Northam and Mayor of Richmond Levar ...
(Date:3/28/2017)... ... , ... For many women, getting birth control isn’t as easy as it should be. In ... access to a health care facility or a pharmacy within 60 minutes of where they ... or for many who are faced with health or personal issues that leave them homebound. ...
(Date:3/28/2017)... ... March 28, 2017 , ... Revolution for Truth ... Congress to protect parental rights and civil liberties, and to restore transparency within ... The demonstration coincides with a press conference taking place Friday morning calling on ...
(Date:3/28/2017)... ... March 28, 2017 , ... Medforce Technologies, Inc., a ... announce it has joined the National Association for Home Care and Hospice (NAHC), ... disabled, and dying Americans of all ages and the caregiver who provide them ...
(Date:3/28/2017)... ... March 28, 2017 , ... Z-Medica, ... University of Pittsburgh Medical Center (UPMC) will acquire QuikClot® Bleeding Control Kits® (BCK) ... program, developed in association with efforts by the American College of Surgeons, U.S. ...
Breaking Medicine News(10 mins):